BUSINESS
    Sanofi Japan Targets AI Fluency across Workforce by End-2027
    By Hayate Horiguchi September 16, 2026
    Sanofi is seeing tangible returns from its company-wide embrace of artificial intelligence in Japan, with employees freeing up around two hours a week through AI-powered tools as the drug maker pushes to embed the technology…

    LATEST

    Mounjaro Label Updated with PIII CV Data Showing Noninferiority
    September 16, 2026
    Eli Lilly Japan and Tanabe Pharma said on September 15 that the Japanese label for their GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 diabetes, has been updated to include the results from the…
    Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
    September 16, 2026
    The clinical value of lipoprotein(a), or Lp(a), remains intact despite the recently reported setback in Novartis’ global PIII cardiovascular outcomes trial of pelacarsen, according to the head of the Japan Atherosclerosis Society (JAS).JAS President Masayuki…
    Keidanren Calls for English Drug Filings to Be Opened to Japan-Based Firms
    September 16, 2026
    The Japan Business Federation, or Keidanren, is calling for Japanese drug makers and other companies with a presence in Japan to be allowed to submit common technical document (CTD) materials in English when filing new drugs for approval.The proposal was…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
    By Tatsuya Otsuka

    Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA